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 Abstract 
  Background:  First we aimed to evaluate the ability of neutrophil gelatinase-associated lipocalin 
(NGAL) and cystatin-C (CyC) in plasma and urine to discriminate between sustained, transient 
and absent acute kidney injury (AKI), and second to evaluate their predictive performance for 
sustained AKI in adult intensive care unit (ICU) patients.   Methods:   A prospective cohort study 
of 700 patients was studied. Sample collection was performed over 8 time points starting on 
admission.   Results:   After exclusion 510 patients remained for the analysis. All biomarkers 
showed significant differentiation between sustained and no AKI at all time points (p  ^  0.0002) 
except for urine CyC (uCyC) on admission (p = 0.06). Urine NGAL (uNGAL) was the only biomark-
er significantly differentiating sustained from transient AKI on ICU admission (p = 0.02). Indi-
vidually, uNGAL performed better than the other biomarkers (area under the curves, AUC = 
0.80, 95% confidence interval, CI = 0.72–0.88) for the prediction of sustained AKI. The combina-
tion with plasma NGAL (pNGAL) showed a nonsignificant improvement (AUC = 0.83, 95% CI = 
0.75–0.91). The combination of individual markers with a model of clinical characteristics (MDRD 
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eGFR, HCO  3  –  and sepsis) did not improve its performance significantly. However, the integrated 
discrimination improvement showed significant improvement when uNGAL was added (p = 
0.04).   Conclusions:   uNGAL measured on ICU admission differentiates patients with sustained 
AKI from transient or no-AKI patients. Combining biomarkers such as pNGAL, uNGAL and plas-
ma CyC with clinical characteristics adds some value to the predictive model. 
  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Acute kidney injury (AKI) is common in adult hospitalized patients and associated with 
significant morbidity and mortality (up to 50%)   [1–3]  . AKI in critically ill patients is rarely 
an isolated event but usually more often part of a more multisystemic immunological condi-
tion contributing to remote organ dysfunction. 
  However, several large cohort studies have established a strong independent relationship 
between the severity of AKI and its associated mortality. Moreover, even small changes in 
kidney function and periods of transient azotemia have considerable impact on outcome  [4] . 
In order to initiate timely therapies, it seems essential to discriminate patients with high risk 
for sustained AKI from patients with lower risk. Unfortunately, at the moment, specific ther-
apies for AKI are lacking even though experimental animal data show promising possibili-
ties. One major setback is that these new agents show promise only in the early reversible 
stages of AKI   [5]  . Therefore, it is essential to possess accurate tools for early detection of sus-
tained AKI. 
    The rise in serum creatinine (SCr) levels is still used for the diagnosis of AKI; conse-
quently it is the basis of AKI definitions such as the RIFLE (risk-injury-failure) criteria. How-
ever, it has a poor predictive value for AKI in the early stage of renal injury. In recent years, 
a number of novel biomarkers have been studied for their potential to detect AKI in its early 
stage   [6] . 
    Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein combined with 
a siderophore, produced by epithelial tissues throughout the human body. It is involved in 
nephrogenesis, induction of nephritic structures from mesenchymal stroma cells, protection 
against ischemic tubular damage and in iron transportation   [7–10]  . Under normal condi-
tions, plasma NGAL (pNGAL) is excreted via glomerular filtration and undergoes complete 
proximal tubular reabsorption. Urine NGAL (uNGAL) is expressed in the distal tubular seg-
ments where it is part of bacterial defense mechanisms. 
    Cystatin-C (CyC) is a 13-kDa nonglycosylated cysteine protease inhibitor produced by 
all nucleated human cells at a constant rate unaffected by muscle mass. Plasma CyC (pCyC) 
is also excreted by glomerular filtration and has a similar catabolic pathway as pNGAL; 
therefore it is not normally found in urine in significant amounts. Some evidence suggests 
that pCyC is a superior functional biomarker compared to SCr especially to detect acute 
changes in estimated glomerular filtration rate (eGFR)   [11, 12]  . 
    Several recent clinical studies have reported encouraging predictive properties of   
NGAL and CyC for AKI development  [12–20] . Despite the reasonable individual biomarker 
performances, it is recognized that biomarker combinations or combined models with clin-
ical   parameters might provide additional accuracy to successfully guide clinical decision 
making   [16] .
    The purpose of this study was to evaluate the discriminative properties of pNGAL, 
  uNGAL, pCyC and uCyC for various AKI disease states and the performance of the bio-
markers on the prediction of developing sustained AKI.11
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  Materials  and  Methods 
 Study  Population 
  Between September 1, 2007, and April 1, 2008, all consecutively admitted patients to the 
adult ICU of the Erasmus University Medical Center in Rotterdam, the Netherlands (where 
general surgical, trauma, medical, neurological and neurosurgical patients but not cardiac 
surgery patients are treated) were considered for participation (n = 700). Exclusion criteria 
were age  ! 18 years, readmission during the study period (only the first admission records were 
included), refusal of informed consent, nephrectomy, chronic kidney disease (CKD, stages 3, 
4 and 5 based on eGFR criteria calculated with the baseline SCr values) and renal transplanta-
tion. Written informed consent was obtained from all participants or their legal representative 
with a deferred consent policy  [21] . The study was approved by the institutional review board.
  Study  Protocol 
  On ICU admission (T = 0) and at 7 time points thereafter (T = 4, 8, 24, 36, 48, 60 and
72 h) plasma and urine sampling was performed using an intra-arterial line and a urine cath-
eter for spot urine. The samples were immediately processed in the hospital’s laboratory and 
the supernatants were stored at –80    °    C. NGAL and CyC concentrations were measured by 
Biosite Inc. in San Diego (Calif., USA) using the Triage   immunoassay. SCr values were mea-
sured in the hospital’s clinical chemical laboratory (using the enzymatic kit produced by 
Roche which is traceable to a reference method based on isotope dilution-mass spectrome-
try) at the time of admission and thereafter daily at 6:     00 a.m. eGFR was calculated using the 
Modification of Diet in Renal Disease (MDRD) Study Equation   [22]   and baseline SCr was 
defined as the patient’s steady state level 4 weeks prior to ICU admission. If not available, the 
admission value was used as the baseline. AKI was defined according to the RIFLE classifi-
cation  [23] . The RIFLE classification is based on the rise in SCr compared to a baseline value. 
Risk represents a 1.5–2 times increase, injury a 2–3 times increase and failure a   1  3 times in-
crease. Sustained AKI was defined as any AKI occurring and persisting for   1  24 h after ad-
mission. Transient AKI was defined as AKI presenting only once and reaching normal SCr 
levels within 24 h. Other variables recorded included age, gender, body mass index, bicarbon-
ate levels (HCO  3  –  ), blood urea nitrogen (BUN) content, white blood cell count (WBC), 
APACHE II (Acute Physiology and Chronic Health Evaluation) score, SOFA (Sequential 
  Organ Failure Assessment) score, cumulative urine output, initiation of renal replacement 
therapy,  diagnosis at discharge, length of ICU stay, ICU mortality and hospital mortality. 
  N G A L   M e a s u r e m e n t s  
 The Triage point-of-care immunoassay was used to determine pNGAL and uNGAL con-
centrations. The detection range is 46–1,300 ng/ml for the pNGAL assay and 2.6–4,100 ng/
ml for the uNGAL assay. Urine samples that had concentrations exceeding the upper limit 
of the assay were diluted with an equal volume of 0.2   M   BES buffer before application to the 
cartridge. The pNGAL assay on this platform has been shown to correlate strongly with 
other methods of pNGAL detection   [24]  .
  CyC  Measurements 
  The Triage point-of-care immunoassay was used to measure CyC in both plasma and 
urine on a research-based cartridge. Plasma samples were measured and calibrated with a 
CyC-spiked plasma pool. The urine assay was calibrated with a urine pool diluted 1:    1  with 
a buffer (0.2   M   BES), which was necessary to dilute the urine samples for appropriate detec-
tion. The performance of the plasma CyC assay was validated against the commercially 
available Dade method. 12
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  D a t a   A n a l y s i s  
  Patients were classified into three groups: no AKI, transient AKI and sustained AKI. 
Demographics and clinical outcomes were summarized and compared among groups. For 
continuous variables, medians and interquartile ranges (IQR) were reported and the Krus-
kal-Wallis test was used to test for group differences. For categorical variables, frequencies 
and proportions were reported and Fisher’s exact test was used to test for group differences. 
    Considering the highly skewed values in some biomarker measurements, medians and 
IQRs were presented for biomarker levels measured at each time point to show the temporal 
trend of biomarker levels over time. At each time point, the medians were compared between 
groups (no AKI, transient AKI and sustained AKI) for all patients and between RIFLE catego-
ries for sustained AKI patients using the rank transformation approach. Tukey-Kramer mul-
tiple comparison adjustment was utilized to adjust for the three pairs of comparisons at each 
time point, and adjusted p values were reported where multiple comparisons were involved.
    To compare the discrimination of sustained AKI versus no AKI and sustained AKI ver-
sus transient AKI using the four biomarkers on admission to the ICU, receiver-operating 
characteristic (ROC) curves were generated and the areas under the curves (AUC) were com-
pared to select the best-performing biomarker. The performance of the combination of 
  uNGAL with other parameters was also investigated to show if there was any improvement 
in the discrimination of AKI patients. 
    Multivariable logistic regression analyses were conducted to assess predictors of sus-
tained AKI and the performance of the predictive models while combining biomarkers with 
clinical factors. The clinical factors considered included MDRD eGFR on admission, diag-
nosis of sepsis and the following laboratory parameters determined on admission: HCO  3  – , 
BUN and WBC. A parsimonious clinical model was first determined based on stepwise 
backward elimination. Each of the four biomarkers was added individually to the parsimo-
nious clinical model and the performance of the predictive models was evaluated using 
Akaike Information Criterion (AIC), the Hosmer-Lemeshow test of goodness of fit, AUC, 
net reclassification improvement (NRI) and integrated discrimination improvement (IDI).
  Statistical analysis was performed using SAS version 9.2 (SAS Institute, Cary, N.C., USA), 
and R package Hmisc (http://CRAN.R-project.org/package = Hmisc) was used to calculate 
NRI and IDI. A significance level of 0.05 was used for all analyses.
  R e s u l t s  
 Patients 
  Seven hundred patients were initially considered to be enrolled in the study. After adopt-
ing the exclusion criteria, 98 patients were excluded. Another 92 patients were excluded be-
cause of established AKI before or on ICU admission, leaving 510 patients in the analysis. Base-
line and clinical characteristics of the patients are presented in   table 1  . Patients with sustained 
AKI had a significantly higher baseline SCr, with correspondingly lower eGFR by the MDRD 
eGFR, lower serum HCO  3  –   levels, higher BUN, higher pNGAL, uNGAL and pCyC values on 
admission, higher APACHE II and SOFA scores, lower 24-hour urine production, higher 24-
hour cumulative fluid balance and significantly increased ICU and hospital mortality.
    Biomarker Performance for Differentiation between No, Transient and Sustained AKI 
  The temporal trends of each biomarker and SCr for patients grouped into no, transient 
and sustained AKI are shown in   figure 1  . All four biomarkers as well as SCr showed signifi-
cant differentiation between sustained AKI and no AKI at all time points (all p   ^   0.0002) 
except for uCyC at the time of ICU admission (p = 0.06;   table 2  ).13
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    The timing of first significant differentiation between sustained AKI and transient AKI 
differed substantially by biomarker. uNGAL was the only biomarker to show significant dif-
ferentiation between sustained and transient AKI on admission and at all time points there-
after (all p   ^   0.02); uCyC significantly differed at T = 4 (p = 0.03) and T = 8 h (p = 0.04); 
pCyC first showed significant differences at 24 h (p = 0.005); pNGAL did not differ until
36 h (p = 0.0002;   table 2  ).
    Differentiation between transient and no AKI was more variable, with pCyC differing 
only at 4 h (p = 0.02); pNGAL differentiating only at 4 and 8 h (p   ^   0.009); SCr differing at 
24, 48 and 72 h (p  ^   0.0008), which is as expected by definition, and uNGAL and uCyC un-
able to distinguish no AKI from transient AKI at any time point on or after ICU admission 
( table 2 ). 
Table 1. B  aseline characteristics and clinical outcome of the patients
No AKI 
(n = 444)
Transient AKI 
(n = 19)
Sustained AKI 
(n = 47)
p value
Age, years 57 (43–68) 60 (45–69) 62 (54–73) 0.07
Male, n (%) 250 (56) 16 (84) 30 (64) 0.03
BMI, kg/m2 24.6 (22.7–27.5) 24.1 (21.9–27.1) 26.0 (23.9–27.8) 0.07
Baseline SCr, mg/dl 0.74 (0.62–0.90) 0.74 (0.68–0.86) 0.90 (0.68–1.02) 0.0007
MDRD eGFR, ml/min 100.0 (86.4–100.0) 100.0 (92.4–100.0) 70.4 (52.2–93.6) <0.0001
SCr, mg/dl 0.75 (0.62–0.89) 0.83 (0.72–0.98) 1.01 (0.74–1.20) <0.0001
HCO3–, mmol/l 22.0 (20.1–24.1) 21.3 (19.9–23.8) 19.7 (17.0–21.8) 0.0001
BUN, mmol/l 5.4 (4.2–7.0) 6.0 (4.2–8.5) 7.2 (4.9–9.4) 0.006
WBC, !109/l 11.2 (8.4–14.9) 9.0 (5.5–13.4) 10.6 (6.0–12.8) 0.02
pNGAL, ng/ml 148.8 (83.2–223.0) 243.4 (154.4–294.7) 286.3 (197.8–412.0) <0.0001
uNGAL, ng/ml 73.1 (34.5–190.8) 89.8 (52.5–276.6) 389.8 (106.3–1833.2) <0.0001
pCyC; mg/l 0.9 (0.8–1.2) 1.1 (1.0–1.3) 1.3 (1.0–1.8) <0.0001
uCyC, mg/l 2.6 (2.6–2.7) 2.6 (2.6–3.5) 2.6 (2.6–3.9) 0.05
APACHE II-24 score 16 (13–22) 22 (15–26) 23 (17–28) <0.0001
SOFA-24 score 4 (2–6) 7.5 (6.0–10.0) 9 (7–12) <0.0001
UP-24, ml/kg/h 1.1 (0.8–1.7) 0.9 (0.6–1.3) 0.8 (0.5–1.3) 0.004
FB-24, ml 1,949 (693–3,815) 4,714 (1,792–5,334) 4,241 (1,774–6,948) <0.0001
RRT, n (%) 0 (0) 0 (0) 7 (15) <0.0001
ICU length of stay, days 4 (2–8) 6 (4–17) 10 (4–17) <0.0001
ICU mortality, n (%) 44 (10) 2 (11) 14 (30) 0.001
Hospital mortality, n (%) 61 (14) 5 (26) 18 (38) 0.0001
Diagnostic group, n (%)
Postoperative 163 (37) 2 (11) 8 (17) –
Medical 82 (18) 2 (11) 7 (15) –
Neurological 92 (21) 3 (16) 4 (9) –
Neurotrauma 27 (6) 2 (11) 1 (2)  –
Multitrauma 30 (7) 4 (21) 4 (9) –
LTx 19 (4) 1 (5) 7 (15) –
Sepsis 12 (3) 1 (5) 5 (11) –
CPR  9 (2) 1 (5) 4 (9) –
Hemorrhagic shock 9 (2) 3 (16) 1 (2) –
MOF 1 (0) 0 (0) 6 (13) –
BMI = Body mass index; APACHE II-24 = APACHE II score during the first 24 h; SOFA-24 = SOFA 
score during the first 24 h; UP-24 = urine production during the first 24 h; FB-24 = fluid balance during 
the first 24 h; RRT = renal replacement therapy; LTx = liver transplantation; CPR = cardiopulmonary re-
suscitation; MOF = multiorgan failure. Medians (IQR) were reported for continuous variables and fre-
quencies (proportions) for categorical variables.14
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  Fig. 1.   Changes in the individual biomarker concentrations over time after ICU admission summarized 
by sustained, transient and no AKI for SCr (  a ) and the four biomarkers pNGAL (  b ), uNGAL (  c ), pCyC (  d ) 
and uCyC (  e  ). Medians and IQR presented on a log  10   scale.  15
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    Biomarker Performance for Differentiation of AKI Severity 
  Patients with sustained AKI were divided into three groups based on their RIFLE cate-
gories (R = risk 1.5- to 2.0-fold increase in baseline SCr; I = injury 2.0–3.0 times, and F = 
failure   1  3 times; n = 47). The temporal trends for each biomarker and SCr are shown in   fig-
ure 2  . Neither pCyC nor uCyC showed significant differentiation among the RIFLE catego-
ries at any time. pNGAL did not significantly differentiate between F and I or between I and 
R, but started to show differentiation between F and R 8 h after ICU admission (p = 0.01). 
The differentiation of RIFLE categories using uNGAL was similar to pNGAL. uNGAL only 
showed significant differentiation between F and R at 4 (p = 0.04), 24 (p = 0.02) and 72 h
(p = 0.049), and between I and R at 24 h (p = 0.03). On and 24 h after ICU admission, SCr 
did not show significant discriminative power among RIFLE categories, and only enabled to 
differentiate F versus R at 48 h (p = 0.0004) and F versus I at 72 h (p = 0.03;   table 2  ).
Table 2. B  iomarker performance for distinguishing different disease states
Biomarker Time since 
admission
h
AKI A  KI RIFLE categories
sustained
vs. no AKI
sustained
vs. transient 
transient
vs. no AKI
failure
 vs.  injury
failure
vs. risk
injury 
vs. risk
pNGAL 0 <0.0001 – – – – –
4 <0.0001 – 0.001 – – –
8 <0.0001 – 0.009 – 0.01 –
24 <0.0001 – – – 0.02 –
36 <0.0001 0.0002 – – 0.03 –
48 <0.0001 0.02 – – 0.03 –
60 <0.0001 – – – – –
72 <0.0001 – – – 0.03 –
uNGAL 0 <0.0001 0.02 – – – –
4 <0.0001 0.01 – – 0.04 –
8 <0.0001 0.002 – – – –
24 <0.0001 0.004 – – 0.02 0.03
36 <0.0001 <0.0001 – – – –
48 <0.0001 0.002 – – – –
60 <0.0001 0.0008 – – – –
72 <0.0001 0.01 – – 0.049 –
pCyC 0 <0.0001 – – – – –
4 <0.0001 – 0.02 – – –
8 <0.0001 – – – – –
24 <0.0001 0.005 – – – –
36 <0.0001 <0.0001 – – – –
48 <0.0001 0.0001 – – – –
60 <0.0001 0.01 – – – –
72 <0.0001 – – – – –
uCyC 0 – – – – – –
4 <0.0001 0.03 – – – –
8 <0.0001 0.04 – – – –
24 <0.0001 – – – – –
36 0.0002 – – – – –
48 <0.0001 – – – – –
60 <0.0001 – – – – –
72 <0.0001 – – – – –
– = Nonsignificant. 16
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  Fig. 2.   Changes in the individual biomarker concentrations over time after ICU admission summarized 
by RIFLE stages risk (R), injury (I) and failure (F) for SCr ( a ) and the four biomarkers pNGAL ( b ), uNGAL 
( c  ), pCyC (  d  ) and uCyC (  e  ). Medians and IQR presented on a log  10   scale. 17
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    Performance of Biomarkers Measured on Admission in the Prediction of Sustained AKI  
 To compare the performance of each individual biomarker in the prediction of AKI and 
to investigate the performance of combinations of biomarkers, subjects who had missing 
  values in one or more biomarkers at the time of admission were excluded for ROC curve 
analysis.
    Four hundred and seventeen patients were included to investigate the discrimination of 
sustained AKI (RIFLE R and above for   1  24 h, n = 37) versus no AKI (n = 380) using differ-
ent biomarkers. All studied biomarkers (pNGAL, uNGAL, pCyC and uCyC) were significant 
predictors of sustained AKI (p  !  0.005). uNGAL showed the best discrimination of sustained 
AKI versus no AKI with an AUC of 0.80 (95% confidence interval, CI = 0.72–0.88) compared 
to pNGAL (AUC = 0.76, 95% CI = 0.67–0.85), pCyC (AUC = 0.71, 95% CI = 0.62–0.80) and 
uCyC (AUC = 0.61, 95% CI = 0.52–0.70;   fig. 3  a). There was no significant difference in AUC 
between uNGAL and pNGAL, or between uNGAL and pCyC, but AUC were significantly 
higher for uNGAL than uCyC (p   !   0.0001). Regarding the discrimination of sustained AKI 
  Fig. 3.    a   ROC curves and corresponding AUCs for the prediction of sustained AKI (n = 37) versus no AKI 
(n = 375) on ICU admission for pNGAL, uNGAL, pCyC and uCyC.   b   ROC curves and corresponding 
AUCs for the prediction of sustained (n = 37) versus transient AKI (n = 17) on ICU admission for pNGAL, 
uNGAL, pCyC and uCyC.   c   ROC curves and corresponding AUCs for the prediction of sustained (n = 37) 
versus no AKI (n = 375) on ICU admission for uNGAL in combination with SCr, pNGAL, pCyC and uCyC. 18
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(n = 37) versus transient AKI (n = 17), uNGAL was the only biomarker which showed sig-
nificance with an AUC of 0.77 (95% CI = 0.64–0.90;   fig. 3  b).
    Biomarker Combinations for the Prediction of Sustained AKI Measured on Admission 
  Combining uNGAL with one of the other three biomarkers did improve the AUCs for 
the discrimination of sustained versus no AKI; however, the improvements were not statisti-
cally significant. The best combination was uNGAL and pNGAL, improving the AUC to 0.83 
(95% CI = 0.75–0.91) from 0.80 with uNGAL alone ( fig. 3 c). There is no improvement in com-
bining biomarkers for the discrimination between sustained and transient AKI.
    Multivariable Logistic Regression Analysis for the Prediction of Sustained AKI 
  To have a fair comparison between the biomarkers, patients with missing values in any 
of the five clinical variables (MDRD eGFR, HCO  3  – , BUN, WBC and sepsis) and the four bio-
markers at the time of ICU admission were excluded from the multivariable logistic regres-
sion analysis. This resulted in a total of 389 patients (33 sustained AKI vs. 356 others). After 
a stepwise backward elimination, MDRD eGFR, HCO  3  –  and diagnosis of sepsis remained in 
the parsimonious clinical model as independent predictors of sustained AKI (p = 0.002,
p = 0.045 and p = 0.0001, respectively). The additional contribution of biomarkers to the pre-
diction of sustained AKI was evaluated by adding each biomarker individually to the parsi-
monious clinical model (  table 3  ). uNGAL and pCyC proved to be significant predictors of 
sustained AKI even with the existence of the three clinical factors. pNGAL was marginally 
significant (p = 0.052) and uCyC was not significant (p = 0.76) after they were added to the 
parsimonious clinical model. The model with uNGAL showed the best goodness of fit based 
on the comparison of AIC (decrease   1  7 in the magnitude of AIC from the clinical model) 
and the Hosmer-Lemeshow test (p = 0.21). There was minor improvement in AUC (0.018–
0.024) when combining a biomarker with the parsimonious clinical model, but the improve-
ment was not statistically significant except for pNGAL (p = 0.03). Additional evaluation of 
the performance of the combined models was conducted by calculating NRI and IDI for each 
combined model versus the parsimonious clinical model. Since no standard scale is available 
for the choice of classification risk levels, NRI was calculated based on the increase or de-
crease of predicted individual probability of developing sustained AKI. Significance was 
shown in NRI for models containing uNGAL (NRI = 0.38, p = 0.04) or pNGAL (NRI = 0.42, 
p = 0.02). Another index for the evaluation of the performance of a predictive model, IDI, 
showed significant improvement for the model containing uNGAL (IDI = 0.06, p = 0.04). 
Considering the components of IDI, the combined model with uNGAL improved classifica-
tion specificity significantly (p = 0.04). 
Table 3. C  omparison of the performance of the predictive models after adding the biomarkers
Model Biomarker
(p value)
AIC H-L test 
(p value)
AUC (95% CI) NRI 
(p value)
IDI 
(p value)
Clinical model – 197.2 0.01 0.79 (0.70–0.89) – –
Clinical + uNGAL 0.0008 188.7 0.21 0.82 (0.73–0.91) 0.38 (0.04) 0.06 (0.04)
Clinical + pNGAL 0.052 195.5 0.01 0.81 (0.72–0.90)* 0.42 (0.02) 0.02 (0.28)
Clinical + uCyC 0.76 199.1 0.01 0.79 (0.70–0.89) –0.25 (0.17) 0.0004 (0.88)
Clinical + pCyC 0.006 191.3 0.02 0.81 (0.72–0.90) 0.08 (0.67) 0.04 (0.09)
H-L = Hosmer-Lemeshow. * p < 0.05 for improvement in AUC vs. clinical model alone.19
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  Discussion 
  This study is the first to our knowledge to demonstrate the utility of uNGAL as a bio-
marker that could be used upon admission to the ICU to distinguish critically ill adults who 
are likely to develop sustained versus transient AKI from those at minimal risk of AKI. Such 
an early clinical determination may allow for the alteration in clinical care toward preven-
tion and early treatment of AKI, prior to the rise in SCr typically used to diagnose AKI. 
However, this study also suggests that NGAL and CyC, either alone or in combination, are 
not able to accurately or persistently discriminate AKI RIFLE severity among critically ill 
patients with developing AKI. Furthermore, although based upon a small event sample size 
the results suggest modest additional value of the markers when added to a model with clin-
ical variables. These negative findings are also important, as they suggest important limita-
tions of these biomarkers in this critical-care setting.
  The cellular and molecular aspects of ischemic and septic AKI are currently being further 
elucidated. Major progress has been made in the knowledge of the underlying pathophysio-
logical mechanisms and possible targets for therapeutic interventions. However, the transla-
tion of these findings to clinical patient-related practice has been disappointing. Different 
pathophysiological stages of AKI have been identified, including a prerenal, initiation, exten-
sion and maintenance phase. Therapy must be considered in the context of these different 
stages, because applying them in the maintenance phase has proven to be unsuccessful. There-
fore, early recognition and discrimination of the first stages of AKI, not yet reflected by func-
tional impairment, are very important   [5, 25]  . To our knowledge, the data presented show for 
the first time that uNGAL is able to provide information on the discrimination between sus-
tained and transient AKI in the early clinical course of AKI development, upon admission to 
the ICU. Such information may prove useful in the early initiation of several emerging treat-
ment modalities, such as innate immune system modulators, growth factors, regulatory T 
cells, cytoprotective agents such as activated protein C, statins and erythropoietin. In addi-
tion, there are issues we would potentially address differently in current practice in patients 
destined for sustained AKI if we could discriminate them from patients with self-limiting 
renal injury. For example, we would attempt a more intense regime of ‘golden hour resuscita-
tion’ with close hemodynamic monitoring of macro- and microcirculation, we would avoid 
nephrotoxic agents and most importantly we would attempt more timely initiation of renal 
replacement therapy to at least control cumulative fluid balances and toxic uremic conditions 
that are clearly correlated with survival and ventilator-free days   [26–31]  . 
    Several studies report promising results for NGAL (AUC ranging from 0.71 to 0.92) 
  [13–16, 32]   and CyC (AUCs ranging from 0.50 to 0.78)   [18, 19, 33–35]   for AKI prediction in 
adult critically ill patients. However, the AUC results are not very consistent and highly de-
pended on the selected patient cohort (e.g. general ICU patients vs. cardiopulmonary bypass 
surgery patients vs. septic patients), and on the inclusion or exclusion of preexisting CKD or 
preexisting AKI. Therefore, newer trends in biomarker research have been directed towards 
the use of biomarker models that include clinical parameters to improve the test accuracy for 
early detection of AKI in well-defined cohorts   [36–38]  . 
  The current study excluded patients with known CKD or AKI, improving the homogene-
ity of our cohort and allowing for an assessment of incident AKI only. It also describes the in-
dividual and combined performance of four different biomarkers (pNGAL, uNGAL, pCyC 
and uCyC) allowing for their direct comparison. In this analysis, the prediction of sustained 
AKI was not significantly different when considering the ROC AUC between pNGAL,  uNGAL, 
pCyC and uCyC. This may be partly explained by the reduction in sample size using patients 
with developing AKI only. Adding the individual biomarkers to a model with clinical charac-
teristics, the improvement in the combined model with uNGAL, pNGAL and pCyC was com-20
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parable, and therefore any potential superiority of a biomarker could not be demonstrated, 
except for uCyC, which was not a significant predictor in the multivariable model.
    Several issues have to be considered concerning potential limitations of this current 
work. 
    (1) Defining a patient’s baseline SCr is a problem in emergency medicine. Not uncom-
monly, these variables are not available due to the absence of the patient’s medical history 
data in the hospital charts. Using the first available SCr value, such as we did, might therefore 
be a reason for some underestimation of AKI severity and might contribute to biomarker test 
nonspecificity. However, the procedures we employed in this study are consistent with the 
clinical determination of AKI. Furthermore, our results have to be considered in a research-
based setting and may not reflect entirely common clinical practice. For the purpose of the 
analysis, this cohort was restricted to patients with developing AKI only, and thus patients 
having reached an increase of   6  50% in SCr before or on admission were excluded. This is 
only possible with the availability of the the patient’s previous SCr baseline values. It is very 
common, however, that in clinical practice the information on a patient’s true baseline SCr 
value is not immediately available and thus the clinical applicability of the differentiation 
between transient and sustained AKI remains to be proven as having additional value. 
  (2) We have to take into account that new biomarkers such as NGAL (injury marker) and 
CyC (functional marker) are tested against a gold standard that has huge imperfections on 
its own. Therefore, we should keep in mind that the lack of sensitivity and specificity of a 
biomarker in the present approach may actually reflect limited use of SCr   [6]  . 
  (3) Urinary values of biomarkers are not corrected for urinary creatinine concentrations; 
however, this is defendable since there is evidence that it is not likely to have a considerable 
impact on overall test performance   [39]  . 
  (4) In this study, exclusion of all patients with CKD rendered the results possibly less ap-
plicable to the general adult intensive-care population where we observe increasing numbers 
of patients entering the ICU with CKD. 
  (5) pNGAL and uNGAL were the only inducible damage markers used in this panel. The 
additional contribution of uCyC in this model was disappointing. 
    Our findings are in contrast with the conclusions of the work of Koyner et al.   [34]   and 
several others stating that CyC may be an improved estimator of GFR particularly in patients 
with very subtle changes in kidney function and injury   [18, 19, 38, 40]  . Recent data demon-
strate that in the absence of CKD, serum CyC and uCyC may be associated with inflamma-
tory biomarkers in an elderly ambulatory population and sepsis in general ICU patients   [41, 
42] . A possible hypothesis is that CyC itself may be a regulator of inflammation, which might 
affect particularly adult critically ill patients with known proinflammatory state. Accord-
ingly, subgroups of this population frequently receive corticosteroid treatment, e.g. sepsis 
and liver transplant patients, and patients suffer from thyroid dysfunction syndromes. Using 
other particular damage markers such as KIM-1 (kidney injury molecule-1)   [43]  , interleu-
kin-18   [44]  , netrin-1   [45, 46]   or liver fatty acid binding proteins   [47]   might potentially have 
a significant additional predictive value to the biomarker panel model, which should be a 
subject of exploration in the near future. 
    In conclusion, we showed that uNGAL accurately discriminates adult patients likely to 
develop sustained AKI from transient AKI at the time of ICU admission. In addition, NGAL 
and CyC, either alone or in combination, were not able to accurately or persistently discrim-
inate AKI RIFLE severity among critically ill patients with developing AKI. However, adding 
uNGAL, pNGAL and pCyC to a model with clinical characteristics slightly improved the 
discrimination of the predictive model, and especially adding uNGAL to the clinical model 
significantly improved the performance of the prediction in terms of both NRI and IDI. 21
Nephron Extra 2011;1:9–23
 DOI:  10.1159/000330428 
EXTRA
  de Geus et al.: uNGAL Predicts Sustained AKI on ICU Admission 
www.karger.com/nne
  © 2011 S. Karger AG, Basel 
  Published online: August 4, 2011     
 References 
   1  Liangos O, Wald R, O’Bell JW, et al: Epidemiology and outcomes of acute renal failure in hospitalized 
patients: a national survey. Clin J Am Soc Nephrol 2006;    1:   43–51. 
   2  Metnitz PG, Krenn CG, Steltzer H, et al: Effect of acute renal failure requiring renal replacement 
therapy on outcome in critically ill patients. Crit Care Med 2002;    30:   2051–2058. 
    3  Uchino S, Kellum JA, Bellomo R, et al: Acute renal failure in critically ill patients: a multinational, 
multicenter study. JAMA 2005;    294:   813–818. 
    4  Uchino S, Bellomo R, Bagshaw SM, et al: Transient azotaemia is associated with a high risk of death 
in hospitalized patients. Nephrol Dial Transplant 2010;    25:   1833–1839. 
    5  Molitoris BA: Transitioning to therapy in ischemic acute renal failure. J Am Soc Nephrol 2003;    14:  
 265–267. 
    6  Waikar SS, Betensky RA, Bonventre JV: Creatinine as the gold standard for kidney injury biomarker 
studies? Nephrol Dial Transplant 2009;    24:   3263–3265. 
    7  Flo TH, Smith KD, Sato S, et al: Lipocalin 2 mediates an innate immune response to bacterial infec-
tion by sequestrating iron. Nature 2004;    432:   917–921. 
    8  Mishra J, Mori K, Ma Q, et al: Amelioration of ischemic acute renal injury by neutrophil gelatinase-
associated lipocalin. J Am Soc Nephrol 2004;    15:   3073–3082. 
    9  Schmidt-Ott KM, Mori K, Kalandadze A, et al: Neutrophil gelatinase-associated lipocalin-mediated 
iron traffic in kidney epithelia. Curr Opin Nephrol Hypertens 2006;    15:   442–449. 
 10  Schmidt-Ott KM, Mori K, Li JY, et al: Dual action of neutrophil gelatinase-associated lipocalin. J Am 
Soc Nephrol 2007;    18:   407–413. 
  11  Dharnidharka VR, Kwon C, Stevens G: Serum cystatin C is superior to serum creatinine as a marker 
of kidney function: a meta-analysis. Am J Kidney Dis 2002;    40:   221–226. 
  12  Nejat M, Pickering JW, Walker RJ, Endre ZH: Rapid detection of acute kidney injury by plasma cys-
tatin C in the intensive care unit. Nephrol Dial Transplant 2010;    25:   3283–3289. 
  13  Constantin JM, Futier E, Perbet S, et al: Plasma neutrophil gelatinase-associated lipocalin is an early 
marker of acute kidney injury in adult critically ill patients: a prospective study. J Crit Care 2010;    25:  
 176.e1–176.e6. 
  14  Cruz DN, de Cal M, Garzotto F, et al: Plasma neutrophil gelatinase-associated lipocalin is an early 
biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010;    36:   444–451. 
  15  Siew ED, Ware LB, Gebretsadik T, et al: Urine neutrophil gelatinase-associated lipocalin moderately 
predicts acute kidney injury in critically ill adults. J Am Soc Nephrol 2009;    20:   1823–1832. 
  16  de Geus HR, Bakker J, Lesaffre EM, le Noble JL: Neutrophil gelatinase-associated lipocalin at ICU 
admission predicts for acute kidney injury in adult patients. Am J Respir Crit Care Med 2011;    183:  
 907–914. 
  Acknowledgments 
  We thank the clinical and laboratory staff of the Erasmus University Medical Center, 
Rotterdam, The Netherlands. We thank Wil Mol, our nurse coordinator, for her contribution 
in patient inclusion and study logistics, as well as the patients and their families for their par-
ticipation. We thank Gillian Parker and Brian Noland from Biosite Inc. (San Diego,   Calif., 
USA) for the measurements of NGAL and CyC levels.
  Disclosure  Statement 
  Biosite Inc. provided biomarker measurements. They had no role in study design and   
conduct, data analysis and reporting. Besides biomarker assessments, no additional funding 
was provided.
 22
Nephron Extra 2011;1:9–23
 DOI:  10.1159/000330428 
EXTRA
  de Geus et al.: uNGAL Predicts Sustained AKI on ICU Admission 
www.karger.com/nne
    © 2011 S. Karger AG, Basel
  Published online: August 4, 2011     
  17  Ahlstrom A, Tallgren M, Peltonen S, et al: Evolution and predictive power of serum cystatin C in 
acute renal failure. Clin Nephrol 2004;    62:   344–350. 
  18  Herget-Rosenthal S, Marggraf G, Hüsing J, et al: Early detection of acute renal failure by serum cys-
tatin C. Kidney Int 2004;    66:   1115–1122. 
  19  Herget-Rosenthal S, Poppen D, Hüsing J, et al: Prognostic value of tubular proteinuria and enzy-
muria in nonoliguric acute tubular necrosis. Clin Chem 2004;    50:   552–558. 
  20  Villa P, Jiménez M, Soriano MC, et al: Serum cystatin C concentration as a marker of acute renal 
dysfunction in critically ill patients. Crit Care 2005;    9:R139–R143. 
  21  Jansen TC, Kompanje EJ, Bakker J: Deferred proxy consent in emergency critical care research: eth-
ically valid and practically feasible. Crit Care Med 2009;    37(1  suppl):S65–S68. 
  22  Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate 
from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study 
Group. Ann Intern Med 1999;    130:   461–470. 
  23  Bellomo R, Ronco C, Kellum JA, et al: Acute renal failure – definition, outcome measures, animal 
models, fluid therapy and information technology needs: the Second International Consensus Con-
ference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;    8:R204–R212. 
  24  Dent CL, Ma Q, Dastrala S, et al: Plasma neutrophil gelatinase-associated lipocalin predicts acute 
kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled 
cohort study. Crit Care 2007;    11:R127. 
  25  Molitoris BA, Sutton TA: Endothelial injury and dysfunction: role in the extension phase of acute 
renal failure. Kidney Int 2004;    66:   496–499. 
 26  Rivers E, Nguyen B, Havstad S, et al: Early goal-directed therapy in the treatment of severe sepsis and 
septic shock. N Engl J Med 2001;    345:   1368–1377. 
  27  Demirkiliç U, Kuralay E, Yenicesu M, et al: Timing of replacement therapy for acute renal failure 
after cardiac surgery. J Card Surg 2004;    19:   17–20. 
  28  Elahi MM, Lim MY, Joseph RN, et al: Early hemofiltration improves survival in post-cardiotomy 
patients with acute renal failure. Eur J Cardiothorac Surg 2004;    26:   1027–1031. 
  29  Liu KD, Himmelfarb J, Paganini E, et al: Timing of initiation of dialysis in critically ill patients with 
acute kidney injury. Clin J Am Soc Nephrol 2006;    1:   915–919. 
  30  Payen D, de Pont AC, Sakr Y, et al: A positive fluid balance is associated with a worse outcome in 
patients with acute renal failure. Crit Care 2008;    12:R74. 
  31  National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical 
Trials Network, Wiedemann HP, Wheeler AP, et al: Comparison of two fluid-management strategies 
in acute lung injury. N Engl J Med 2006;    354:   2564–2575. 
 32  Nickolas TL, O’Rourke MJ, Yang J, et al: Sensitivity and specificity of a single emergency department 
measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney in-
jury. Ann Intern Med 2008;    148:   810–819. 
 33  Haase-Fielitz A, Bellomo R, Devarajan P, et al: Novel and conventional serum biomarkers predicting 
acute kidney injury in adult cardiac surgery – a prospective cohort study. Crit Care Med 2009;    37:  
 553–560. 
  34  Koyner JL, Bennett MR, Worcester EM, et al: Urinary cystatin C as an early biomarker of acute kid-
ney injury following adult cardiothoracic surgery. Kidney Int 2008;    74:   1059–1069. 
  35  Liangos O, Tighiouart H, Perianayagam MC, et al: Comparative analysis of urinary biomarkers for 
early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009;    14:   423–
431. 
  36  Nolen B, Velikokhatnaya L, Marrangoni A, et al: Serum biomarker panels for the discrimination of 
benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;    117:   440–445. 
  37  Shapiro NI, Trzeciak S, Hollander JE, et al: A prospective, multicenter derivation of a biomarker 
panel to assess risk of organ dysfunction, shock, and death in emergency department patients with 
suspected sepsis. Crit Care Med 2009;    37:   96–104. 
  38  Coca SG, Yalavarthy R, Concato J, et al: Biomarkers for the diagnosis and risk stratification of acute 
kidney injury: a systematic review. Kidney Int 2008;    73:   1008–1016. 
  39  Mishra J, Dent C, Tarabishi R, et al: Neutrophil gelatinase-associated lipocalin (NGAL) as a bio-
marker for acute renal injury after cardiac surgery. Lancet 2005;    365:   1231–1238. 
 40  Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin 
Chem 2002;    48:   699–707. 23
Nephron Extra 2011;1:9–23
 DOI:  10.1159/000330428 
EXTRA
  de Geus et al.: uNGAL Predicts Sustained AKI on ICU Admission 
www.karger.com/nne
  © 2011 S. Karger AG, Basel 
  Published online: August 4, 2011     
  41  Keller CR, Odden MC, Fried LF, et al: Kidney function and markers of inflammation in elderly per-
sons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 2007;   
 71:   239–244. 
  42  Nejat M, Pickering JW, Walker RJ, et al: Urinary cystatin C is diagnostic of acute kidney injury and 
sepsis, and predicts mortality in the intensive care unit. Crit Care 2010;    14:R85. 
 43  Liangos O, Perianayagam MC, Vaidya VS, et al: Urinary N-acetyl-  - D -glucosaminidase activity and 
kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc 
Nephrol 2007;    18:   904–912. 
  44  Parikh CR, Mishra J, Thiessen-Philbrook H, et al: Urinary IL-18 is an early predictive biomarker of 
acute kidney injury after cardiac surgery. Kidney Int 2006;    70:   199–203. 
  45  Brian Reeves W, Kwon O, Ramesh G: Netrin-1 and kidney injury. II. Netrin-1 is an early biomarker 
of acute kidney injury. Am J Physiol Renal Physiol 2008;    294:F731–F738. 
  46  Ramesh G, Krawczeski CD, Woo JG, Wang Y, Devarajan P: Urinary netrin-1 is an early predictive 
biomarker of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2010;    5:   395–401. 
  47  Portilla D, Dent C, Sugaya T, et al: Liver fatty acid-binding protein as a biomarker of acute kidney 
injury after cardiac surgery. Kidney Int 2008;    73:   465–472. 
  